© 2020 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Thyroid Cancers
Real-World Data Support Use of Multikinase Inhibitors in Differentiated Thyroid Cancer
October 20, 2020
In an interview with Targeted Oncology, Marcia Brose, MD, PhD, discussed the findings for the global, non-interventional study that assessed the use of sorafenib as treatment of patients with asymptomatic radioiodine-refractory differentiated thyroid cancer.
TRK Fusions Help to Fulfill Unmet Need in Thyroid Cancer Treatment Landscape
October 16, 2020
Maria E. Cabanillas, MD, discusses the treatment landscape for patients with thyroid cancers harboring a TRK fusion.
ESMO Data Show Benefit of Approved Thyroid Cancer Regimens in Select Patients
October 14, 2020
Across subsets of patients with thyroid cancer, an interesting collection of research was shared with oncologists during the 2020 European Society of Medical Oncology Virtual Congress, demonstrating improvement in outcomes for patients with thyroid cancers with newer and established approved regimens.
Patient-Reported Outcomes Confirm Tolerability of Selpercatinib in RET-Driven Thyroid Cancer
October 12, 2020
In an interview with Targeted Oncology, Lori J. Wirth, MD, discussed the findings from an analysis of the patient-reported outcomes observed in the LIBRETTO-001 study of selpercatinib in patients with RET-driven thyroid cancers.
A 73-Year-Old Woman With Differentiated Thyroid Cancer
September 25, 2020
Andrew G. Gianoukakis, MD, of Harbor-UCLA Medical Center, describes the rationale for treating a patient with RAI-refractory differentiated thyroid cancer with systemic therapy.
Early Data Presented for Lenvatinib and Pembrolizumab in Thyroid Cancer
September 23, 2020
Christine Dierks, MD, discusses the early data from a study looking at the combination of lenvatinib and pembrolizumab in patients with metastatic anaplastic or poorly differentiated thyroid carcinoma.
Larotrectinib Induces Promising Response Rate in Patients With Differentiated Thyroid Cancer
September 21, 2020
Larotrectinib as treatment of patients with TRK fusion-positive thyroid cancer had rapid and durable disease control, with the highest response rates observed in the differentiated thyroid cancer population.
A 71-Year-Old Woman with NTRK Gene Fusion Thyroid Cancer
September 21, 2020
A key opinion leader reviews the case of a 71-year-old woman with NTRK gene fusion thyroid cancer and considers novel therapies available for the management of her disease.
Larotrectinib Elicits Rapid, Durable Responses in TRK Fusion-Positive Solid Tumors
September 20, 2020
Larotrectinib demonstrated rapid and durable as treatment of patients with TRK fusion-positive solid tumors, as well as a favorable long-term toxicity profile, according to an expanded pooled analysis from 3 clinical trials.
Ongoing ARROW Trial Data Support Pralsetinib as a Potential Treatment Option in RET-Mutant MTC
September 20, 2020
Patients with medullary thyroid cancer harboring abberations in RET who were treated with pralsetinib across therapy lines exhibited potent and durable clinical activity, according to results presented at the ESMO Virtual Congress 2020 from the phase 1/2 ARROW clinical trial.